Utrecht (The Netherlands), Cambridge (United States) – Respiratory device producer Vapotherm, Inc. announced its Initial Public Offering and listing on the NYSE exchange. Shares in the IPO are issued to institutional investors in the US and Europe, raising gross proceeds of $56 million. The offering was significantly oversubscribed. The total market capitalisation of Vapotherm will be $244 million at the introduction price and shares will trade under the ticker symbol VAPO.
The new funds enable Vapotherm to continue ramping sales of its Hi-VNI® technology in the US and Europe. Vapotherm’s Hi-VNI® treats patients in respiratory distress in the neo-natal intensive care unit (ICU), the adult ICU, the emergency department, post-acute care and for patients in hospice. The technology has been proven equivalent to the gold standard of non-invasive ventilation, however can be delivered without the need for a mask, providing patients with more comfort and flexibility in their care.
In addition to ramping sales with existing products, Vapotherm will use proceeds from the IPO to pursue an aggressive product development program which includes products which automate the delivery of oxygen based on feedback from a patient’s oxygen levels; and a portable device which has the potential to be used in expanded clinical settings, including the home.
Gilde Healthcare acted as lead investor in the Series B financing for Vapotherm and will remain represented on the board of Vapotherm post listing. During Gilde’s investment period Vapotherm tripled US and International revenues, established a highly specialized direct sales force, and dramatically increased gross margins.
Bank of America Merrill Lynch and William Blair acted as Joint Bookrunners in connection with the IPO. Canaccord Genuity acted as lead manager and BTIG acted as co-manager.
About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a private equity fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com
